Clinical trials: Smoking
Tobacco Smoking, Tobacco Use
Room Air Levels of Harmful and Potentially Harmful Constituents After Heated Tobacco Product Use and Cigarettes
This study is designed to assess and characterize levels of selected harmful and potentially harmful constituents (HPHCs) and other endpoints of interest in an environmental chamber (EC) after ad libitum use of Ploom® heated…
- Trial name
- NCT06476405
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Altria Client Services LLC
Smoking Cessation
The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
This three-group randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e-cigarette.
- Trial name
- NCT05205811
- Testing
- Bupropion, Zonisamide, E-cigarette
- Where
- 2 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation, Harm Reduction
Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders
To determine whether smokers who initially respond (within 2 weeks) to nicotine products (including nicotine replacement therapy, e-cigarettes, nicotine pouches) by reducing their smoking by ≥50% can be successfully maintained on…
- Trial name
- NCT06554873
- Testing
- Nicoderm, Nicorette 4Mg Chewing Gum, Nicorette Lozenge Product
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation, Harm Reduction
Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine
This study will evaluate the effects of a reward devaluation strategy, which has been researched in the past, combined/augmented with the medication d-cycloserine in assisting smokers to switch from combustible cigarette (CC) to…
- Trial name
- NCT05994703
- Testing
- d-cycloserine, Juul e-cigarette
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking Cessation
A Study of Cytisinicline for Smoking Cessation in Adult Smokers
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for…
- Trial name
- ORCA-2 (NCT04576949)
- Testing
- Cytisinicline, Behavioral support
- Where
- 17 sites in United States
- Volunteers
- 810 people
- Sponsor
- Achieve Life Sciences
Smoking Cessation
A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline TID for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of…
- Trial name
- ORCA-3 (NCT05206370)
- Testing
- Cytisinicline, Behavioral support
- Where
- 12 sites in United States
- Volunteers
- 792 people
- Sponsor
- Achieve Life Sciences
Smoking, Smoking Behaviors
Abuse Liability for Eight Electronic Nicotine Products
This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]), and plasma nicotine…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT07323511
- Testing
- Product A, Product B, Product C
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Smoking Behaviors
A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems
This will be an open-label, randomized, single-site, 8-way crossover study designed to evaluate plasma nicotine pharmacokinetic (PK) parameters and overall product liking (OPL) following an ad libitum use of Electronic Nicotine…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT07323563
- Testing
- Product A, Product B, Product C
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Smoking Behaviors
Abuse Liability for Five Modern Oral Nicotine Products
This is a two-site, open-label, randomized, 4-way (2 arm) cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT07132814
- Testing
- Product A, Product B, Product C
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Tobacco Use
Modern Nicotine Oral Product Abuse Liability
This is a two-site, open-label, randomized, 8-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine uptake…
- Trial name
- NCT06777784
- Testing
- Product A, Product B, Product C
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cigarette
A Consumer Use Behavior Study to Evaluate Puffing Topography and Average Daily Consumption of Heated Tobacco Products
This is a parallel design cohort consumer use study to measure the puffing topography of two HTP devices, with three variants of HTP consumables ("sticks,"), collectively referred to as the study investigational products (Study…
- Trial name
- NCT07175987
- Testing
- RDTH002581, RDTH002580, RDTH002582
- Where
- United Kingdom
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking, Smoking Behaviors
Abuse Liability for Four Heated Tobacco Product (HTP) Consumables and Two HTP Devices
This is a single-site, open-label, randomized, 8-way crossover study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT07267195
- Testing
- Product A, Product N, Product B
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cessation, Vaping Cessation
Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers
Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.
- Trial name
- ORCA-OL (NCT06435221)
- Testing
- Cytisinicline
- Where
- 29 sites in United States
- Volunteers
- 479 people
- Sponsor
- Achieve Life Sciences
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Smoking Cessation
Study of a Smartphone-Based Switch Program
Prospective, open label, single center clinical study enrolling up to 120 participants to evaluate the Pivot cigarette smoking cessation program in adult smokers, previously unable to quit, who also use other smoke-free nicotine…
- Trial name
- NCT06544772
- Testing
- Pivot cigarette smoking cessation program
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Pivot Health Technologies Inc.
Bullying, Cyberbullying
Using Digital Health Technology to Prevent Bullying and Cyberbullying Among Elementary School Students
This project is designed to address the urgent need for an effective primary prevention approach to the problem of bullying and cyberbullying among elementary school students.
- Conditions
- Bullying, Cyberbullying, Smoking
- Trial name
- NCT06592872
- Testing
- Bullying prevention
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Christopher Williams
Smoking Cessation
CoQuit Study for Smoking Cessation
This study investigated the feasibility of a cognitive dissonance-based mobile app for smoking cessation (CDI). Cognitive dissonance refers to the conflict between beliefs and behaviors; interventions are designed to promote this…
- Trial name
- NCT04893460
- Testing
- CoQuit App
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Smoking, Abdominal Aortic Aneurysm
Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.
The purpose of this study was to evaluate the reduction of the Abdominal Aortic Aneurysm (AAA) annual growth rate in patients who switched from smoking cigarettes to using IQOS as compared to patients who continued to smoke…
- Conditions
- Smoking, Abdominal Aortic Aneurysm, IQOS Use
- Trial name
- NCT03837704
- Testing
- IQOS, Cigarette, Smoking Cessation
- Where
- 13 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation, Nicotine Dependence
Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy
CESTO 2 is a 318 participants, 3-arm, multicentric, randomized, double-blind, placebo-controlled Phase II clinical trial. The main objectives are to select the most efficient dose and to assess long-term efficacy of NFL-101…
- Trial name
- CESTO2 (NCT04571216)
- Testing
- NFL-101 dose 1, NFL-101 dose 2
- Where
- 9 sites in France
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- NFL Biosciences SAS
Smoking Cessation
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
This study will explore the efficacy and tolerability of centanafadine at a dose of 400 mg per day of centanafadine in promoting smoking abstinence in adult smokers seeking to quit.
- Trial name
- NCT05066724
- Testing
- Centanafadine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.